Serrapeptase
•Last Updated: September 28 2022
Serrapeptase is an enzyme derived from silkworms. It has anti-inflammatory effects and can help prevent blood clots, but these effects are somewhat unreliable.
Serrapeptase is most often used for
Last Updated: September 28 2022
Serrapeptase is a proteolytic (protein destroying) enzyme from bacteria native to the digestive system of silkworms. It is the enzyme responsible for dissolving a silkworm’s cocoon.
Traditionally, serrapeptase has been used for its anti-inflammatory properties. Today, it is marketed as a joint health supplement.
Unfortunately, many studies on serrapeptase were poorly structured, with inadequate control groups. The most recent data suggests that serrapeptase is not a very effective supplement, as far as joint health and inflammation is concerned.
Though serrapeptase has been detected in plasma after supplementation, the standard oral dose for serrapeptase is low, which means very little is absorbed through the intestines. This may be one of the reasons serrapeptase is unreliable and not very effective.
Serrapeptase has been found to have the ability to liquefy mucus and reduce bacterial biofilms (reducing bacteria’s ability to stick to surfaces and each other). This means serrapeptase may be able to reduce phlegm buildup, nasal discharge, lung symptoms of cystic fibrosis and help other compounds fight bacteria. Additional research is needed to confirm these effects.
Note that Serrapeptase is also known as:
- Serratiopeptidase
- Serratia E-15
- serralysin
- serratiaprotease
- Silk worm enzymes
The standard dose for serrapeptase is 10-60mg.
Serrapeptase should be supplemented on an empty stomach, which is 30 minutes before a meal or two hours after a meal, three times a day. Most studies use 10mg of serrapeptase taken every eight hours.
More human evidence is needed to determine the optimal dose of serrapeptase. 10mg of serrapeptase is equal to approximately 20,000 enzymatic units.
Evidence + Benefits at a glance
Easily compare what works and what doesn't.
1.^Bhagat S, Agarwal M, Roy VSerratiopeptidase: a systematic review of the existing evidenceInt J Surg.(2013)
2.^Badhe RV, Nanda RK, Kulkarni MB, Bhujbal MN, Patil PS, Badhe SRMedia optimization studies for Serratiopeptidase production from Serratia marcescens ATCC 13880Hindustan Antibiot Bull.(2009)
3.^Purification and characterization of four proteases from a clinical isolate of Serratia marcescens kums 3958.()
4.^Pansuriya R, Singhal REffects of dissolved oxygen and agitation on production of serratiopeptidase by Serratia marcescens NRRL B-23112 in stirred tank bioreactor and its kinetic modelingJ Microbiol Biotechnol.(2011 Apr)
5.^CASTANEDA-AGULLO MStudies on the biosynthesis of extracellular proteases by bacteria. I. Serratia marcescens, synthetic and gelatin mediaJ Gen Physiol.(1956 Jan 20)
6.^Bromke BJ, Hammel JMRegulation of extracellular protease formation by Serratia marcescensCan J Microbiol.(1979 Jan)
7.^Matsumoto K, Maeda H, Takata K, Kamata R, Okamura RPurification and characterization of four proteases from a clinical isolate of Serratia marcescens kums 3958J Bacteriol.(1984 Jan)
8.^Selan L, Berlutti F, Passariello C, Comodi-Ballanti MR, Thaller MCProteolytic enzymes: a new treatment strategy for prosthetic infectionsAntimicrob Agents Chemother.(1993 Dec)
11.^Umashankar MS, Sachdeva RK, Gulati MAquasomes: a promising carrier for peptides and protein deliveryNanomedicine.(2010 Jun)
12.^Rawat M, Singh D, Saraf S, Saraf SDevelopment and in vitro evaluation of alginate gel-encapsulated, chitosan-coated ceramic nanocores for oral delivery of enzymeDrug Dev Ind Pharm.(2008 Feb)
13.^Moriya N, Nakata M, Nakamura M, Takaoka M, Iwasa S, Kato K, Kakinuma AIntestinal absorption of serrapeptase (TSP) in ratsBiotechnol Appl Biochem.(1994 Aug)
14.^Woodley JFEnzymatic barriers for GI peptide and protein deliveryCrit Rev Ther Drug Carrier Syst.(1994)
15.^KV S, Devi GS, Mathew STLiposomal formulations of serratiopeptidase: in vitro studies using PAMPA and Caco-2 modelsMol Pharm.(2008 Jan-Feb)
16.^Camenisch G, Folkers G, van de Waterbeemd HShapes of membrane permeability-lipophilicity curves: extension of theoretical models with an aqueous pore pathwayEur J Pharm Sci.(1998 Oct)
17.^Obata K, Sugano K, Saitoh R, Higashida A, Nabuchi Y, Machida M, Aso YPrediction of oral drug absorption in humans by theoretical passive absorption modelInt J Pharm.(2005 Apr 11)
18.^Nirale NM, Menon MDTopical formulations of serratiopeptidase: development and pharmacodynamic evaluationIndian J Pharm Sci.(2010 Jan)
19.^Shah MH, Paradkar ACubic liquid crystalline glyceryl monooleate matrices for oral delivery of enzymeInt J Pharm.(2005 Apr 27)
20.^Kakinuma A, Moriya N, Kawahara K, Sugino HRepression of fibrinolysis in scalded rats by administration of Serratia proteaseBiochem Pharmacol.(1982 Sep 15)
21.^Al-Khateeb TH, Nusair YEffect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molarsInt J Oral Maxillofac Surg.(2008 Mar)
22.^Kee WH, Tan SL, Lee V, Salmon YMThe treatment of breast engorgement with Serrapeptase (Danzen): a randomised double-blind controlled trialSingapore Med J.(1989 Feb)
23.^Malshe PCA preliminary trial of serratiopeptidase in patients with carpal tunnel SyndromeJ Assoc Physicians India.(2000 Nov)
24.^Jadav SP, Patel NH, Shah TG, Gajera MV, Trivedi HR, Shah BKComparison of anti-inflammatory activity of serratiopeptidase and diclofenac in albino ratsJ Pharmacol Pharmacother.(2010 Jul)
25.^Tachibana M, Mizukoshi O, Harada Y, Kawamoto K, Nakai YA multi-centre, double-blind study of serrapeptase versus placebo in post-antrotomy buccal swellingPharmatherapeutica.(1984)
26.^Chopra D, Rehan HS, Mehra P, Kakkar AKA randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain modelInt J Oral Maxillofac Surg.(2009 Apr)
27.^Murugesan K, Sreekumar K, Sabapathy BComparison of the roles of serratiopeptidase and dexamethasone in the control of inflammation and trismus following impacted third molar surgeryIndian J Dent Res.(2012 Nov-Dec)
28.^Panagariya A, Sharma AKA preliminary trial of serratiopeptidase in patients with carpal tunnel syndromeJ Assoc Physicians India.(1999 Dec)
29.^Esch PM, Gerngross H, Fabian AReduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase-- a prospective studyFortschr Med.(1989 Feb 10)
30.^Bracale G, Selvetella LClinical study of the efficacy of and tolerance to seaprose S in inflammatory venous disease. Controlled study versus serratio-peptidaseMinerva Cardioangiol.(1996 Oct)
31.^Relevant Role of Fibronectin-Binding Proteins in Staphylococcus aureus Biofilm-Associated Foreign-Body Infections.()
32.^Christner M, Franke GC, Schommer NN, Wendt U, Wegert K, Pehle P, Kroll G, Schulze C, Buck F, Mack D, Aepfelbacher M, Rohde HThe giant extracellular matrix-binding protein of Staphylococcus epidermidis mediates biofilm accumulation and attachment to fibronectinMol Microbiol.(2010 Jan)
33.^Kaplan JBBiofilm dispersal: mechanisms, clinical implications, and potential therapeutic usesJ Dent Res.(2010 Mar)
34.^Artini M, Papa R, Scoarughi GL, Galano E, Barbato G, Pucci P, Selan LComparison of the action of different proteases on virulence properties related to the staphylococcal surfaceJ Appl Microbiol.(2013 Jan)
35.^Artini M, Scoarughi GL, Papa R, Cellini A, Carpentieri A, Pucci P, Amoresano A, Gazzola S, Cocconcelli PS, Selan LA new anti-infective strategy to reduce adhesion-mediated virulence in Staphylococcus aureus affecting surface proteinsInt J Immunopathol Pharmacol.(2011 Jul-Sep)
36.^Longhi C, Scoarughi GL, Poggiali F, Cellini A, Carpentieri A, Seganti L, Pucci P, Amoresano A, Cocconcelli PS, Artini M, Costerton JW, Selan LProtease treatment affects both invasion ability and biofilm formation in Listeria monocytogenesMicrob Pathog.(2008 Jul)
38.^Costerton JW, Cheng KJ, Geesey GG, Ladd TI, Nickel JC, Dasgupta M, Marrie TJBacterial biofilms in nature and diseaseAnnu Rev Microbiol.(1987)
39.^Lee HS, Majima Y, Sakakura Y, Kim BWA technique for quantitative cytology of nasal secretionsEur Arch Otorhinolaryngol.(1991)
40.^Nakamura S, Hashimoto Y, Mikami M, Yamanaka E, Soma T, Hino M, Azuma A, Kudoh SEffect of the proteolytic enzyme serrapeptase in patients with chronic airway diseaseRespirology.(2003 Sep)
41.^Majima Y, Hirata K, Takeuchi K, Hattori M, Sakakura YEffects of orally administered drugs on dynamic viscoelasticity of human nasal mucusAm Rev Respir Dis.(1990 Jan)
42.^Majima Y, Inagaki M, Hirata K, Takeuchi K, Morishita A, Sakakura YThe effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucusArch Otorhinolaryngol.(1988)
43.^Shimura S, Okubo T, Maeda S, Aoki T, Tomioka M, Shindo Y, Takishima T, Umeya KEffect of expectorants on relaxation behavior of sputum viscoelasticity in vivoBiorheology.(1983)
44.^Mecikoglu M, Saygi B, Yildirim Y, Karadag-Saygi E, Ramadan SS, Esemenli TThe effect of proteolytic enzyme serratiopeptidase in the treatment of experimental implant-related infectionJ Bone Joint Surg Am.(2006 Jun)
45.^Ishihara Y, Kitamura S, Takaku FExperimental studies on distribution of cefotiam, a new beta-lactam antibiotic, in the lung and trachea of rabbits. II. Combined effects with serratiopeptidaseJpn J Antibiot.(1983 Oct)
46.^Aratani H, Tateishi H, Negita SStudies on the distributions of antibiotics in the oral tissues: Experimental staphylococcal infection in rats, and effect of serratiopeptidase on the distributions of antibiotics (author's transl)Jpn J Antibiot.(1980 May)
47.^Viswanatha Swamy AH, Patil PAEffect of some clinically used proteolytic enzymes on inflammation in ratsIndian J Pharm Sci.(2008 Jan)
48.^Shimizu H, Ueda M, Takai T, Bito T, Ichihashi M, Muramatsu T, Shirai TA case of serratiopeptidase-induced subepidermal bullous dermatosisBr J Dermatol.(1999 Dec)
Primary Use
Ear, Nose & ThroatSecondary Use